Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jessica Merrill

New York, NY
Jessica Merrill is a Bureau Editor for US Commercial Content for Informa’s pharmaceutical news publications, including “The Pink Sheet” and SCRIP. She has been covering the pharmaceutical industry as a journalist for more than 10 years, spanning the spectrum from R&D to regulatory to commercial. She was previously a reporter and editor for “The Pink Sheet” and “Pink Sheet” DAILY, specializing in business and commercial news, focusing largely on big pharma, M&A and business development, and the commercial landscape, including drug launches and market access. Before embarking on a career in healthcare journalism, she covered business news for the cosmetics industry and worked as a newspaper reporter.
Advertisement
Set Alert for Articles By Jessica Merrill

Latest From Jessica Merrill

Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce

Troubled Teva has been preparing employees for layoffs, but the final plan will reshape the generic drug giant entirely with 14,000 jobs being cut in a scramble to stabilize the company. Every business area and geography will be affected.

Generic Drugs Business Strategies

An ASH That Moves The Ball – And The Ticker Price

The American Society of Hematology meeting showcased breakthroughs and some ho-hum news, resulting in rollercoaster-like crests and troughs for biotech stocks.

Clinical Trials Companies

Pharma 'All-Stars' Talk Hot Topics At Forbes Summit

Some of pharma's biggest names debated the pressing issues impacting industry, including pricing, image and the inter partes review system. Then, a cancer patient stood up and asked a question that reminded everyone of the issues facing patients.

Leadership Intellectual Property

CVS/Aetna To Merge In Defensive Play To Reshape Health-Care Delivery

The pharmacy retail chain and drug distributor will buy the insurer for $69bn in a merger to build what the companies say will be a new, more affordable health-care concept.

Deals Distribution

CVS/Aetna To Merge In Defensive Play To Reshape Healthcare Delivery

The pharmacy retail chain and drug distributor will buy the insurer for $69bn in a merger to build what the companies say will be a new, more affordable healthcare concept.

Distribution Reimbursement

The Rebate Debate: Forbes Panelists On How Rebates Trickle Down To Patients

Express Scripts CEO Timothy Wentworth and PhRMA President Steven Ubl discussed some of the issues around drug rebating practices at the Forbes Healthcare Summit, including point-of-sale rebates.

Market Access Pricing Debate
See All
Advertisement
UsernamePublicRestriction

Register